{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:47:37Z","timestamp":1793976457682,"version":"4.8.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["Daiichi Sankyo"],"award-info":[{"award-number":["Daiichi Sankyo"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40264-023-01328-x","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T10:02:20Z","timestamp":1691488940000},"page":"927-949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8320-3166","authenticated-orcid":false,"given":"Joanne Wing Yan","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-6419","authenticated-orcid":false,"given":"Soo Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4499-5284","authenticated-orcid":false,"given":"James Chung-man","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4156-9212","authenticated-orcid":false,"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1451-1939","authenticated-orcid":false,"given":"Ta-Chung","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5588-8332","authenticated-orcid":false,"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-8838","authenticated-orcid":false,"given":"Elgene","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-4056","authenticated-orcid":false,"given":"Ching-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-9171","authenticated-orcid":false,"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Ying","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-9458","authenticated-orcid":false,"given":"Lynette Li San","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0863-8469","authenticated-orcid":false,"given":"Winnie","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6421-7602","authenticated-orcid":false,"given":"Rebecca","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"issue":"4785","key":"1328_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235(4785):177\u201382. https:\/\/doi.org\/10.1126\/science.3798106.","journal-title":"Science"},{"issue":"1","key":"1328_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","volume":"9","author":"CL Arteaga","year":"2011","unstructured":"Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9(1):16\u201332. https:\/\/doi.org\/10.1038\/nrclinonc.2011.177.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1328_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S1470-2045(21)00349-1","volume":"22","author":"MV Dieci","year":"2021","unstructured":"Dieci MV, Miglietta F. HER2: a never ending story. Lancet Oncol. 2021;22(8):1051\u20132. https:\/\/doi.org\/10.1016\/S1470-2045(21)00349-1.","journal-title":"Lancet Oncol"},{"issue":"23","key":"1328_CR4","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.22.00519","volume":"40","author":"SH Giordano","year":"2022","unstructured":"Giordano SH, Franzoi MAB, Temin S, et al. Systemic therapy for advanced human epidermal growth factor receptor 2\u2013positive breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(23):2612\u201335. https:\/\/doi.org\/10.1200\/JCO.22.00519.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1328_CR5","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"issue":"1","key":"1328_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41523-022-00434-w","volume":"8","author":"F Miglietta","year":"2022","unstructured":"Miglietta F, Griguolo G, Bottosso M, et al. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer. 2022;8(1):66. https:\/\/doi.org\/10.1038\/s41523-022-00434-w.","journal-title":"NPJ Breast Cancer."},{"issue":"5","key":"1328_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/cancers13051015","volume":"13","author":"D Eiger","year":"2021","unstructured":"Eiger D, Agostinetto E, Sa\u00fade-Conde R, de Azambuja E. The exciting new field of HER2-low breast cancer treatment. Cancers (Basel). 2021;13(5):1015. https:\/\/doi.org\/10.3390\/cancers13051015.","journal-title":"Cancers (Basel)."},{"issue":"20","key":"1328_CR8","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1328_CR9","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(17)30604-6.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1328_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","volume":"20","author":"K Tamura","year":"2019","unstructured":"Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):816\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(19)30097-X.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1328_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"issue":"12","key":"1328_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2115022.","journal-title":"N Engl J Med"},{"issue":"1","key":"1328_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"1328_CR14","unstructured":"US Food & Drug Administration. FDA grants regular approval to fam-trastuzumab deruxtecan-nxki for breast cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer. Accessed Dec 2022."},{"key":"1328_CR15","unstructured":"US Food & Drug Administration. FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer. Accessed 11 July 2023."},{"key":"1328_CR16","unstructured":"US food & Drug Administration. FDA Approves First Targeted Therapy for HER2-Low Breast Cancer. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-therapy-her2-low-breast-cancer. Accessed 11 July 2023."},{"key":"1328_CR17","unstructured":"European Medicines Agency. Enhertu. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enhertu#authorisation-details-section. Accessed 11 July 2023."},{"key":"1328_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41746-020-0277-8","volume":"3","author":"AJ Averitt","year":"2020","unstructured":"Averitt AJ, Weng C, Ryan P, Perotte A. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. NPJ Digit Med. 2020;3:67. https:\/\/doi.org\/10.1038\/s41746-020-0277-8.","journal-title":"NPJ Digit Med."},{"issue":"34","key":"1328_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3346\/jkms.2018.33.e213","volume":"33","author":"HS Kim","year":"2018","unstructured":"Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33(34):213. https:\/\/doi.org\/10.3346\/jkms.2018.33.e213.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"1328_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40801-019-0159-z","volume":"6","author":"JP Boissel","year":"2019","unstructured":"Boissel JP, Cogny F, Marko N, Boissel FH. From clinical trial efficacy to real-life effectiveness: why conventional metrics do not work. Drugs Real World Outcomes. 2019;6(3):125\u201332. https:\/\/doi.org\/10.1007\/s40801-019-0159-z.","journal-title":"Drugs Real World Outcomes."},{"issue":"1","key":"1328_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1159\/000441818","volume":"14","author":"N Duma","year":"2018","unstructured":"Duma N, Vera Aguilera J, Paludo J, et al. Representation of minorities and women in oncology clinical trials: review of the past 14 Years. J Oncol Pract. 2018;14(1):e1-10. https:\/\/doi.org\/10.1159\/000441818.","journal-title":"J Oncol Pract"},{"issue":"6","key":"1328_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000441818","volume":"10","author":"L Fan","year":"2015","unstructured":"Fan L, Goss PE, Strasser-Weippl K. Current status and future projections of breast cancer in Asia. Breast Care (Basel). 2015;10(6):372\u20138.","journal-title":"Breast Care (Basel)."},{"issue":"1","key":"1328_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12916-022-02260-0","volume":"20","author":"KA Hirko","year":"2022","unstructured":"Hirko KA, Rocque G, Reasor E, et al. The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology. BMC Med. 2022;20(1):72. https:\/\/doi.org\/10.1186\/s12916-022-02260-0.","journal-title":"BMC Med"},{"issue":"1","key":"1328_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s43441-020-00193-5","volume":"55","author":"RJ LoCasale","year":"2021","unstructured":"LoCasale RJ, Pashos CL, Gutierrez B, et al. Bridging the gap between RCTs and RWE through endpoint selection. Ther Innov Regul Sci. 2021;55(1):90\u20136. https:\/\/doi.org\/10.1007\/s43441-020-00193-5.","journal-title":"Ther Innov Regul Sci."},{"key":"1328_CR25","unstructured":"Daiichi Sankyo. DESTINY-Breast01. Clinical Study Protocol."},{"key":"1328_CR26","unstructured":"Daiichi Sankyo. DESTINY-Breast03. Clinical Study Protocol."},{"key":"1328_CR27","unstructured":"Daiichi Sankyo. DESTINY-Breast04. Clinical Study Protocol."},{"key":"1328_CR28","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","volume":"106","author":"SM Swain","year":"2022","unstructured":"Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106:102378. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102378.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"1328_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/oncolo\/oyac107","volume":"27","author":"A Bardia","year":"2022","unstructured":"Bardia A, Harnden K, Mauro L, Pennisi A, Armitage M, Soliman H. Clinical practices and institutional protocols on prophylaxis, monitoring, and management of selected adverse events associated with trastuzumab deruxtecan. Oncologist. 2022;27(8):637\u201345. https:\/\/doi.org\/10.1093\/oncolo\/oyac107.","journal-title":"Oncologist"},{"key":"1328_CR30","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2017006","volume":"39","author":"E Choi","year":"2017","unstructured":"Choi E, Lee S, Nhung BC, et al. Cancer mortality-to-incidence ratio as an indicator of cancer management outcomes in Organization for Economic Cooperation and Development countries. Epidemiol Health. 2017;39: e2017006. https:\/\/doi.org\/10.4178\/epih.e2017006.","journal-title":"Epidemiol Health."},{"issue":"6","key":"1328_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000502637","volume":"14","author":"D Trapani","year":"2019","unstructured":"Trapani D, Curigliano G, Eniu A. Breast cancer: Reimbursement policies and adoption of new therapeutic agents by national health systems. Breast Care (Basel). 2019;14(6):373\u201381. https:\/\/doi.org\/10.1159\/000502637.","journal-title":"Breast Care (Basel)."},{"issue":"3","key":"1328_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4048\/jbc.2022.25.e21","volume":"25","author":"S Ithimakin","year":"2022","unstructured":"Ithimakin S, Parinyanitikul N, Kim SB, et al. Disparities in access to systemic treatment for breast cancer in Thailand and major Asian territories. J Breast Cancer. 2022;25(3):207\u201317. https:\/\/doi.org\/10.4048\/jbc.2022.25.e21.","journal-title":"J Breast Cancer"},{"issue":"2","key":"1328_CR33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/app5.76","volume":"2","author":"A Smullen","year":"2015","unstructured":"Smullen A, Hong PK. Comparing the health care systems of high-performing Asian countries. Asia Pac Policy Stud. 2015;2(2):347\u201355. https:\/\/doi.org\/10.1002\/app5.76.","journal-title":"Asia Pac Policy Stud"},{"key":"1328_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012373960-5.00305-1","author":"GM Leung","year":"2008","unstructured":"Leung GM, Wagstaff A, Lindelow M, Lu JR. China, Hong Kong and Taiwan, Health Systems of. Int Encycl Public Health. 2008. https:\/\/doi.org\/10.1016\/B978-012373960-5.00305-1.","journal-title":"Int Encycl Public Health."},{"issue":"10305","key":"1328_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(21)00252-X","volume":"398","author":"CC Tan","year":"2021","unstructured":"Tan CC, Lam CSP, Matchar DB, Zee YK, Wong JEL. Singapore\u2019s health-care system: Key features, challenges, and shifts. Lancet. 2021;398(10305):1091\u2013104. https:\/\/doi.org\/10.1016\/S0140-6736(21)00252-X.","journal-title":"Lancet"},{"issue":"1","key":"1328_CR36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1186\/s12885-021-08756-x","volume":"21","author":"AJ Rodriguez-Acevedo","year":"2021","unstructured":"Rodriguez-Acevedo AJ, Chan RJ, Olsen CM, Pandeya N, Whiteman DC, Gordon LG. Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia. BMC Cancer. 2021;21(1):1055. https:\/\/doi.org\/10.1186\/s12885-021-08756-x.","journal-title":"BMC Cancer"},{"issue":"7","key":"1328_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201552","volume":"13","author":"DE Goldsbury","year":"2018","unstructured":"Goldsbury DE, Yap S, Weber MF, et al. Health services costs for cancer care in Australia: Estimates from the 45 and Up Study. PLoS ONE. 2018;13(7): e0201552. https:\/\/doi.org\/10.1371\/journal.pone.0201552.","journal-title":"PLoS ONE"},{"issue":"4","key":"1328_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","volume":"11","author":"P Nasa","year":"2021","unstructured":"Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol. 2021;11(4):116\u201329. https:\/\/doi.org\/10.5662\/wjm.v11.i4.116.","journal-title":"World J Methodol."},{"issue":"2","key":"1328_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccm.2021.03.001","volume":"42","author":"SA Guler","year":"2021","unstructured":"Guler SA, Corte TJ. Interstitial lung disease in 2020: A history of progress. Clin Chest Med. 2021;42(2):229\u201339. https:\/\/doi.org\/10.1016\/j.ccm.2021.03.001.","journal-title":"Clin Chest Med"},{"issue":"6","key":"1328_CR40","doi-asserted-by":"publisher","first-page":"2100276","DOI":"10.1183\/13993003.00276-2021","volume":"58","author":"CJ Ryerson","year":"2021","unstructured":"Ryerson CJ, Corte TJ, Myers JL, Walsh SLF, Guler SA. A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease. Eur Respir J. 2021;58(6):2100276. https:\/\/doi.org\/10.1183\/13993003.00276-2021.","journal-title":"Eur Respir J"},{"issue":"4","key":"1328_CR41","doi-asserted-by":"publisher","first-page":"2102776","DOI":"10.1183\/13993003.02776-2021","volume":"60","author":"P Spagnolo","year":"2022","unstructured":"Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V. Drug-induced interstitial lung disease. Eur Respir J. 2022;60(4):2102776. https:\/\/doi.org\/10.1183\/13993003.02776-2021.","journal-title":"Eur Respir J"},{"issue":"4","key":"1328_CR42","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11523-019-00656-2","volume":"14","author":"AECAB Willemsen","year":"2019","unstructured":"Willemsen AECAB, Tol J, van Erp NP, et al. Prospective study of drug-induced interstitial lung disease in advanced breast cancer patients receiving everolimus plus exemestane. Target Oncol. 2019;14(4):441\u201351. https:\/\/doi.org\/10.1007\/s11523-019-00656-2.","journal-title":"Target Oncol"},{"issue":"1","key":"1328_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1402","volume":"5","author":"H Nawa","year":"2022","unstructured":"Nawa H, Niimura T, Yagi K, Goda M, Zamami Y, Ishizawa K. Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments. Cancer Rep (Hoboken). 2022;5(1): e1402. https:\/\/doi.org\/10.1002\/cnr2.1402.","journal-title":"Cancer Rep (Hoboken)."},{"issue":"4","key":"1328_CR44","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2169\/internalmedicine.2779-19","volume":"59","author":"M Murakami","year":"2020","unstructured":"Murakami M, Kanemura H, Tomishima Y, Nakano E, Tamura T. Eribulin-induced interstitial pneumonia: A case series and retrospective cohort study. Intern Med. 2020;59(4):563\u20137. https:\/\/doi.org\/10.2169\/internalmedicine.2779-19.","journal-title":"Intern Med"},{"issue":"2","key":"1328_CR45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4103\/lungindia.lungindia_126_21","volume":"39","author":"TM Anoop","year":"2022","unstructured":"Anoop TM, Joseph R, Unnikrishnan P, Thomas F, Venugopal M. Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge. Lung India. 2022;39(2):158\u201368. https:\/\/doi.org\/10.4103\/lungindia.lungindia_126_21.","journal-title":"Lung India"},{"issue":"4","key":"1328_CR46","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7(4):100554. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554.","journal-title":"ESMO Open."},{"key":"1328_CR47","doi-asserted-by":"crossref","unstructured":"Powell CA, Modi S, Iwata H, et al. 92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd). Ann Oncol. 2021;32:S61\u20132. https:\/\/www.annalsofoncology.org\/article\/S0923-7534(21)00984-4\/fulltext. Accessed 11 July 2023.","DOI":"10.1016\/j.annonc.2021.03.106"},{"issue":"10371","key":"1328_CR48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5.","journal-title":"Lancet"},{"issue":"16_suppl","key":"1328_CR49","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"40","author":"JK Kish","year":"2022","unstructured":"Kish JK, Mehta S, Kwong J, et al. Monitoring and management of interstitial lung disease\/pneumonitis among patients with metastatic breast cancer treated with trastuzumab deruxtecan. J Clin Oncol. 2022;40(16_suppl):1036. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5.","journal-title":"J Clin Oncol"},{"key":"1328_CR50","doi-asserted-by":"crossref","unstructured":"Im SA, Xu B, Kim SB, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 (PS2-1). In Japanese Society of Medical Oncology Annual Meeting. 2022. Kyoto, Japan. https:\/\/www.c-linkage.co.jp\/jsmo2022\/en\/contents\/program.html. Accessed 11 July 2023.","DOI":"10.1016\/j.annonc.2022.05.064"},{"issue":"4","key":"1328_CR51","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","volume":"51","author":"K Kubo","year":"2013","unstructured":"Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51(4):260\u201377. https:\/\/doi.org\/10.1016\/j.resinv.2013.09.001.","journal-title":"Respir Investig"},{"issue":"12","key":"1328_CR52","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","volume":"7","author":"P Tarantino","year":"2021","unstructured":"Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7(12):1873\u201381. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3595.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1328_CR53","doi-asserted-by":"publisher","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","volume":"7","author":"P Conte","year":"2022","unstructured":"Conte P, Ascierto PA, Patelli G, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7(2):100404. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100404.","journal-title":"ESMO Open."},{"issue":"4","key":"1328_CR54","doi-asserted-by":"publisher","first-page":"100553","DOI":"10.1016\/j.esmoop.2022.100553","volume":"7","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022;7(4):100553. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100553.","journal-title":"ESMO Open."},{"key":"1328_CR55","unstructured":"European Medicines Agency. Summary of product characteristics. ENHERTU. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enhertu-epar-product-information_en-0.pdf Accessed 11 July 2023."},{"key":"1328_CR56","unstructured":"US Food & Drug Administration. Prescribing Information. ENHERTU. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761139s011lbl.pdf. Accessed 11 July 2023."},{"key":"1328_CR57","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 11 July 2023."},{"issue":"1","key":"1328_CR58","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13244-021-01131-1","volume":"12","author":"H Liu","year":"2021","unstructured":"Liu H, Liu Y, Zhao L, Li X, Zhang W. Preprocedural fasting for contrast-enhanced CT: when experience meets evidence. Insights Imaging. 2021;12(1):180. https:\/\/doi.org\/10.1186\/s13244-021-01131-1.","journal-title":"Insights Imaging"},{"issue":"8","key":"1328_CR59","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17383","volume":"13","author":"R Houston","year":"2021","unstructured":"Houston R, Mahato B, Odell T, Khan YR, Mahato D. The financial and radiation burden of early reimaging in neurosurgical patients: an original study and review of the literature. Cureus. 2021;13(8): e17383. https:\/\/doi.org\/10.7759\/cureus.17383.","journal-title":"Cureus."},{"issue":"12","key":"1328_CR60","doi-asserted-by":"publisher","first-page":"902","DOI":"10.4329\/wjr.v8.i12.902","volume":"8","author":"SP Power","year":"2016","unstructured":"Power SP, Moloney F, Twomey M, James K, O\u2019Connor OJ, Maher MM. Computed tomography and patient risk: facts, perceptions and uncertainties. World J Radiol. 2016;8(12):902\u201315. https:\/\/doi.org\/10.4329\/wjr.v8.i12.902.","journal-title":"World J Radiol."},{"issue":"12","key":"1328_CR61","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.4065\/mcp.2010.0260","volume":"85","author":"EC Lin","year":"2010","unstructured":"Lin EC. Radiation risk from medical imaging. Mayo Clin Proc. 2010;85(12):1142\u20136. https:\/\/doi.org\/10.4065\/mcp.2010.0260.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"1328_CR62","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4329\/wjr.v7.i8.189","volume":"7","author":"EJ van Beek","year":"2015","unstructured":"van Beek EJ, Mirsadraee S, Murchison JT. Lung cancer screening: computed tomography or chest radiographs? World J Radiol. 2015;7(8):189\u201393. https:\/\/doi.org\/10.4329\/wjr.v7.i8.189.","journal-title":"World J Radiol."},{"issue":"1","key":"1328_CR63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000452225","volume":"93","author":"L Vizioli","year":"2017","unstructured":"Vizioli L, Ciccarese F, Forti P, et al. Integrated use of lung ultrasound and chest X-ray in the detection of interstitial lung disease. Respiration. 2017;93(1):15\u201322. https:\/\/doi.org\/10.1159\/000452225.","journal-title":"Respiration"},{"key":"1328_CR64","unstructured":"Afzal F, Raza S, Shafique M. Diagnostic accuracy of X-ray chest in interstitial lung disease as confirmed by high resolution computed tomography (HRCT) chest. Pak Armed Forces Med J. 2017;67(4):593\u201398. https:\/\/www.pafmj.org\/index.php\/PAFMJ\/article\/view\/699. Accessed 11 July 2023."},{"issue":"1","key":"1328_CR65","doi-asserted-by":"publisher","first-page":"7669","DOI":"10.1038\/s41598-021-87452-z","volume":"11","author":"M Karayama","year":"2021","unstructured":"Karayama M, Aoshima Y, Yasui H, et al. Simple method for detecting idiopathic interstitial pneumonias by measuring vertical lung length on chest X-ray. Sci Rep. 2021;11(1):7669. https:\/\/doi.org\/10.1038\/s41598-021-87452-z.","journal-title":"Sci Rep"},{"issue":"150","key":"1328_CR66","doi-asserted-by":"publisher","first-page":"180073","DOI":"10.1183\/16000617.0073-2018","volume":"27","author":"SLF Walsh","year":"2018","unstructured":"Walsh SLF, Devaraj A, Enghelmayer JI, et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180073. https:\/\/doi.org\/10.1183\/16000617.0073-2018.","journal-title":"Eur Respir Rev"},{"issue":"6","key":"1328_CR67","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1183\/09031936.00150314","volume":"44","author":"AE Holland","year":"2014","unstructured":"Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society\/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428\u201346. https:\/\/doi.org\/10.1183\/09031936.00150314.","journal-title":"Eur Respir J"},{"issue":"1","key":"1328_CR68","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41533-022-00268-w","volume":"32","author":"K Oishi","year":"2022","unstructured":"Oishi K, Matsunaga K, Asami-Noyama M, et al. The 1-minute sit-to-stand test to detect desaturation during 6-minute walk test in interstitial lung disease. NPJ Prim Care Respir Med. 2022;32(1):5. https:\/\/doi.org\/10.1038\/s41533-022-00268-w.","journal-title":"NPJ Prim Care Respir Med."},{"key":"1328_CR69","first-page":"A97","volume":"77","author":"S Barth","year":"2022","unstructured":"Barth S, Edwards C, Saini G, et al. P33 What affects acceptability of remote digital monitoring of spirometry in patients with interstitial lung disease? Thorax. 2022;77:A97\u20138.","journal-title":"Thorax"},{"issue":"4","key":"1328_CR70","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S2589-7500(21)00276-4","volume":"4","author":"A Alboksmaty","year":"2022","unstructured":"Alboksmaty A, Beaney T, Elkin S, et al. Effectiveness and safety of pulse oximetry in remote patient monitoring of patients with COVID-19: a systematic review. Lancet Digit Health. 2022;4(4):e279\u201389. https:\/\/doi.org\/10.1016\/S2589-7500(21)00276-4.","journal-title":"Lancet Digit Health."},{"key":"1328_CR71","doi-asserted-by":"publisher","unstructured":"Gold WM, Koth LL. Pulmonary function testing. In: Murray and Nadel's Textbook of respiratory medicine. 2016:407\u201335. https:\/\/doi.org\/10.1016\/B978-1-4557-3383-5.00025-7.","DOI":"10.1016\/B978-1-4557-3383-5.00025-7"},{"issue":"1","key":"1328_CR72","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13075-022-02786-x","volume":"24","author":"T Hoffmann","year":"2022","unstructured":"Hoffmann T, Oelzner P, Franz M, et al. Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases. Arthritis Res Ther. 2022;24(1):107. https:\/\/doi.org\/10.1186\/s13075-022-02786-x.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1328_CR73","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/imj.14647","volume":"50","author":"A Bui","year":"2020","unstructured":"Bui A, Han S, Alexander M, Toner G, Irving L, Manser R. Pulmonary function testing for the early detection of drug-induced lung disease: a systematic review in adults treated with drugs associated with pulmonary toxicity. Intern Med J. 2020;50(11):1311\u201325. https:\/\/doi.org\/10.1111\/imj.14647.","journal-title":"Intern Med J"},{"issue":"1","key":"1328_CR74","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09031936.05.00034505","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Resp J. 2005;26(1):153\u201361. https:\/\/doi.org\/10.1183\/09031936.05.00034505.","journal-title":"Eur Resp J."},{"issue":"3","key":"1328_CR75","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.chest.2020.06.065","volume":"51","author":"HJ Cheung","year":"2015","unstructured":"Cheung HJ, Cheung L. Coaching patients during pulmonary function testing: a practical guide. Can J Respir Ther. 2015;51(3):65\u20138. https:\/\/doi.org\/10.1016\/j.chest.2020.06.065.","journal-title":"Can J Respir Ther."},{"issue":"6","key":"1328_CR76","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/j.chest.2020.06.065","volume":"158","author":"A Kouri","year":"2020","unstructured":"Kouri A, Gupta S, Yadollahi A, et al. Addressing reduced laboratory-based pulmonary function testing during a pandemic. Chest. 2020;158(6):2502\u201310.","journal-title":"Chest"},{"issue":"1","key":"1328_CR77","doi-asserted-by":"publisher","first-page":"00602","DOI":"10.1183\/23120541.00602-2021","volume":"8","author":"A McGowan","year":"2022","unstructured":"McGowan A, Laveneziana P, Bayat S, et al. International consensus on lung function testing during the COVID-19 pandemic and beyond. ERJ Open Res. 2022;8(1):00602\u20132021. https:\/\/doi.org\/10.1183\/23120541.00602-2021.","journal-title":"ERJ Open Res."},{"issue":"2","key":"1328_CR78","doi-asserted-by":"publisher","first-page":"00209","DOI":"10.1183\/23120541.00209-2018","volume":"5","author":"L Richeldi","year":"2019","unstructured":"Richeldi L, Launders N, Martinez F, et al. The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. ERJ Open Res. 2019;5(2):00209\u20132018. https:\/\/doi.org\/10.1183\/23120541.00209-2018.","journal-title":"ERJ Open Res."},{"issue":"5","key":"1328_CR79","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44-68. https:\/\/doi.org\/10.1164\/rccm.201807-1255ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1328_CR80","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7861\/clinmedicine.17-2-146","volume":"17","author":"TA Mikolasch","year":"2017","unstructured":"Mikolasch TA, Garthwaite HS, Porter JC. Update in diagnosis and management of interstitial lung disease. Clin Med (Lond). 2017;17(2):146\u201353. https:\/\/doi.org\/10.7861\/clinmedicine.17-2-146.","journal-title":"Clin Med (Lond)"},{"issue":"9","key":"1328_CR81","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1164\/rccm.201202-0320ST","volume":"185","author":"KC Meyer","year":"2012","unstructured":"Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004\u201314. https:\/\/doi.org\/10.1164\/rccm.201202-0320ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 10","key":"1328_CR82","doi-asserted-by":"publisher","first-page":"S996","DOI":"10.21037\/jtd.2017.06.39","volume":"9","author":"J Kebbe","year":"2017","unstructured":"Kebbe J, Abdo T. Interstitial lung disease: the diagnostic role of bronchoscopy. J Thorac Dis. 2017;9(Suppl 10):S996-1010. https:\/\/doi.org\/10.21037\/jtd.2017.06.39.","journal-title":"J Thorac Dis"},{"issue":"2","key":"1328_CR83","doi-asserted-by":"publisher","first-page":"362","DOI":"10.21037\/jtd.2017.02.48","volume":"9","author":"H Yamakawa","year":"2017","unstructured":"Yamakawa H, Hagiwara E, Kitamura H, et al. Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease. J Thorac Dis. 2017;9(2):362\u201371. https:\/\/doi.org\/10.21037\/jtd.2017.02.48.","journal-title":"J Thorac Dis"},{"issue":"1","key":"1328_CR84","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1164\/ajrccm.162.1.9903014","volume":"162","author":"H Takahashi","year":"2000","unstructured":"Takahashi H, Kuroki Y, Tanaka H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med. 2000;162(1):258\u201363. https:\/\/doi.org\/10.1164\/ajrccm.162.1.9903014.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1328_CR85","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/hematology.2020000116","volume":"2020","author":"L Malpica","year":"2020","unstructured":"Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematol Am Soc Hematol Educ Program. 2020;2020(1):319\u201327. https:\/\/doi.org\/10.1182\/hematology.2020000116.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"1328_CR86","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/jmv.27421","volume":"94","author":"Y Yamamoto","year":"2022","unstructured":"Yamamoto Y, Shiroyama T, Hirata H, et al. Prolonged corticosteroid therapy and cytomegalovirus infection in patients with severe COVID-19. J Med Virol. 2022;94(3):1067\u201373. https:\/\/doi.org\/10.1002\/jmv.27421.","journal-title":"J Med Virol"},{"issue":"3","key":"1328_CR87","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10388-012-0316-x","volume":"9","author":"Y Sato","year":"2012","unstructured":"Sato Y, Motoyama S, Maruyama K, et al. CMV reactivation caused by methylprednisolone therapy for ARDS after esophagectomy. Esophagus. 2012;9(3):141\u20136. https:\/\/doi.org\/10.1007\/s10388-012-0316-x.","journal-title":"Esophagus"},{"issue":"24","key":"1328_CR88","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782\u201397. https:\/\/doi.org\/10.1200\/JCO.20.01296.","journal-title":"J Clin Oncol"},{"key":"1328_CR89","unstructured":"National Comprehensive Cancer Network. Antiemesis. 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 11 July 2023."},{"issue":"Suppl 1","key":"1328_CR90","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00520-018-4147-8","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro M. Searching for perfection: Further progress in management of chemotherapy-induced nausea and vomiting-introduction. Support Care Cancer. 2018;26(Suppl 1):3\u20134. https:\/\/doi.org\/10.1007\/s00520-018-4147-8.","journal-title":"Support Care Cancer"},{"issue":"4","key":"1328_CR91","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3390\/cancers14041022","volume":"14","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, Arpino G, Biganzoli L, et al. Emetogenicity of antibody-drug conjugates (ADCs) in solid tumors with a focus on trastuzumab deruxtecan: insights from an Italian expert panel. Cancers (Basel). 2022;14(4):1022. https:\/\/doi.org\/10.3390\/cancers14041022.","journal-title":"Cancers (Basel)."},{"key":"1328_CR92","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2020.00329","volume":"11","author":"ASM Mosa","year":"2020","unstructured":"Mosa ASM, Hossain AM, Lavoie BJ, et al. Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol. 2020;11:329. https:\/\/doi.org\/10.3389\/fphar.2020.00329.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1328_CR93","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(2):242\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1328_CR94","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00520-018-4400-1","volume":"27","author":"S Chanthawong","year":"2019","unstructured":"Chanthawong S, Lim YH, Subongkot S, et al. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. Support Care Cancer. 2019;27(3):1109\u201319. https:\/\/doi.org\/10.1007\/s00520-018-4400-1.","journal-title":"Support Care Cancer"},{"key":"1328_CR95","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.359","author":"S Sun","year":"2022","unstructured":"Sun S, Ko YH, Jin JY, et al. Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial. Korean J Intern Med. 2022. https:\/\/doi.org\/10.3904\/kjim.2020.359.","journal-title":"Korean J Intern Med"},{"key":"1328_CR96","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fphar.2017.00019","volume":"8","author":"BL Rapoport","year":"2017","unstructured":"Rapoport BL. Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management. Front Pharmacol. 2017;8:19. https:\/\/doi.org\/10.3389\/fphar.2017.00019.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1328_CR97","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/09114300.2018.1451593","volume":"41","author":"T Kondo","year":"2018","unstructured":"Kondo T, Amano K. Era of steroid sparing in the management of immune-mediated inflammatory diseases. Immunol Med. 2018;41(1):6\u201311. https:\/\/doi.org\/10.1080\/09114300.2018.1451593.","journal-title":"Immunol Med"},{"issue":"28","key":"1328_CR98","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199\u2013212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488.","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"1328_CR99","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw325.","journal-title":"Ann Oncol"},{"issue":"15","key":"1328_CR100","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42(15):2433\u201353. https:\/\/doi.org\/10.1016\/j.ejca.2006.05.002.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1328_CR101","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3390\/ph14111200","volume":"14","author":"JH Choi","year":"2021","unstructured":"Choi JH, Geum MJ, Kang JE, Park NG, Oh YK, Rhie SJ. Clinical outcomes of secondary prophylactic granulocyte colony-stimulating factors in breast cancer patients at a risk of neutropenia with doxorubicin and cyclophosphamide-based chemotherapy. Pharmaceuticals (Basel). 2021;14(11):1200. https:\/\/doi.org\/10.3390\/ph14111200.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"1328_CR102","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.mcna.2016.09.003","volume":"101","author":"MJ Cascio","year":"2017","unstructured":"Cascio MJ, DeLoughery TG. Anemia: Evaluation and diagnostic tests. Med Clin N Am. 2017;101(2):263\u201384. https:\/\/doi.org\/10.1016\/j.mcna.2016.09.003.","journal-title":"Med Clin N Am"},{"issue":"11","key":"1328_CR103","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1136\/gutjnl-2021-325210","volume":"70","author":"J Snook","year":"2021","unstructured":"Snook J, Bhala N, Beales ILP, et al. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. 2021;70(11):2030\u201351. https:\/\/doi.org\/10.1136\/gutjnl-2021-325210.","journal-title":"Gut"},{"issue":"Suppl 4","key":"1328_CR104","doi-asserted-by":"publisher","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","volume":"29","author":"M Aapro","year":"2018","unstructured":"Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv96-110. https:\/\/doi.org\/10.1093\/annonc\/mdx758.","journal-title":"Ann Oncol"},{"key":"1328_CR105","unstructured":"National Comprehensive Cancer Network. Hematopoietic growth factors. 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf. Accessed 11 July 2023."},{"key":"1328_CR106","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/JEP.S262349","volume":"13","author":"C Madeddu","year":"2021","unstructured":"Madeddu C, Neri M, Sanna E, Oppi S, Macci\u00f2 A. Experimental drugs for chemotherapy- and cancer-related anemia. J Exp Pharmacol. 2021;13:593\u2013611. https:\/\/doi.org\/10.2147\/JEP.S262349.","journal-title":"J Exp Pharmacol"},{"issue":"7","key":"1328_CR107","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/blood.2019004017","volume":"136","author":"JA Gilreath","year":"2020","unstructured":"Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020;136(7):801\u201313.","journal-title":"Blood"},{"issue":"15","key":"1328_CR108","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1200\/JCO.18.02142","volume":"37","author":"J Bohlius","year":"2019","unstructured":"Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336\u201351. https:\/\/doi.org\/10.1200\/JCO.18.02142.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1328_CR109","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JOP.2017.028902","volume":"36","author":"CA Schiffer","year":"2018","unstructured":"Schiffer CA, Bohlke K, Delaney M, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(3):283\u201399. https:\/\/doi.org\/10.1200\/JOP.2017.028902.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1328_CR110","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","volume":"107","author":"DJ Kuter","year":"2022","unstructured":"Kuter DJ. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica. 2022;107(6):1243\u201363. https:\/\/doi.org\/10.3324\/haematol.2021.279512.","journal-title":"Haematologica"},{"issue":"4","key":"1328_CR111","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","volume":"106","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2021;106(4):1148\u201357. https:\/\/doi.org\/10.3324\/haematol.2020.251900.","journal-title":"Haematologica"},{"issue":"6","key":"1328_CR112","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","volume":"106","author":"ES Winer","year":"2017","unstructured":"Winer ES, Safran H, Karaszewska B, et al. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. Int J Hematol. 2017;106(6):765\u201376. https:\/\/doi.org\/10.1007\/s12185-017-2319-9.","journal-title":"Int J Hematol"},{"issue":"9","key":"1328_CR113","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3238\/arztebl.2012.0161","volume":"109","author":"M Horneber","year":"2012","unstructured":"Horneber M, Fischer I, Dimeo F, R\u00fcffer JU, Weis J. Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. Dtsch Arztebl Int. 2012;109(9):161\u201371. https:\/\/doi.org\/10.3238\/arztebl.2012.0161.","journal-title":"Dtsch Arztebl Int"},{"issue":"10","key":"1328_CR114","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","volume":"11","author":"JE Bower","year":"2014","unstructured":"Bower JE. Cancer-related fatigue\u2013mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597\u2013609. https:\/\/doi.org\/10.1038\/nrclinonc.2014.127.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1328_CR115","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1177\/2156587216676122","volume":"22","author":"D Weber","year":"2017","unstructured":"Weber D, O\u2019Brien K. Cancer and cancer-related fatigue and the interrelationships with depression, stress, and inflammation. J Evid Based Complementary Altern Med. 2017;22(3):502\u201312. https:\/\/doi.org\/10.1177\/2156587216676122.","journal-title":"J Evid Based Complementary Altern Med"},{"issue":"17","key":"1328_CR116","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.annonc.2020.02.016","volume":"32","author":"JE Bower","year":"2014","unstructured":"Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol. 2014;32(17):1840\u201350. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.016.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1328_CR117","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.annonc.2020.02.016","volume":"31","author":"A Fabi","year":"2020","unstructured":"Fabi A, Bhargava R, Fatigoni S, et al. Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment. Ann Oncol. 2020;31(6):713\u201323.","journal-title":"Ann Oncol"},{"issue":"4","key":"1328_CR118","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/ijnmr.IJNMR_63_17","volume":"23","author":"L Mardanian-Dehkordi","year":"2018","unstructured":"Mardanian-Dehkordi L, Kahangi L. The Relationship between perception of social support and fatigue in patients with cancer. Iran J Nurs Midwifery Res. 2018;23(4):261\u20136. https:\/\/doi.org\/10.4103\/ijnmr.IJNMR_63_17.","journal-title":"Iran J Nurs Midwifery Res"},{"issue":"3","key":"1328_CR119","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jpainsymman.2015.11.020","volume":"51","author":"LL Zhang","year":"2016","unstructured":"Zhang LL, Wang SZ, Chen HL, Yuan AZ. Tai Chi exercise for cancer-related fatigue in patients with lung cancer undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manag. 2016;51(3):504\u201311. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.11.020.","journal-title":"J Pain Symptom Manag"},{"key":"1328_CR120","doi-asserted-by":"publisher","first-page":"684058","DOI":"10.3389\/fmed.2021.684058","volume":"8","author":"R Wang","year":"2021","unstructured":"Wang R, Huang X, Wu Y, Sun D. Efficacy of Qigong exercise for treatment of fatigue: a systematic review and meta-analysis. Front Med (Lausanne). 2021;8:684058. https:\/\/doi.org\/10.3389\/fmed.2021.684058.","journal-title":"Front Med (Lausanne)."},{"key":"1328_CR121","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejon.2019.09.003","volume":"42","author":"Z Gok Metin","year":"2019","unstructured":"Gok Metin Z, Karadas C, Izgu N, Ozdemir L, Demirci U. Effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in early breast cancer patients: an assessor blinded, three-arm, randomized controlled trial. Eur J Oncol Nurs. 2019;42:116\u201325. https:\/\/doi.org\/10.1016\/j.ejon.2019.09.003.","journal-title":"Eur J Oncol Nurs"},{"issue":"3","key":"1328_CR122","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000519817","volume":"8","author":"CR Moattari","year":"2022","unstructured":"Moattari CR, Jafferany M. Psychological aspects of hair disorders: Consideration for dermatologists, cosmetologists, aesthetic, and plastic surgeons. Skin Appendage Disord. 2022;8(3):186\u201394. https:\/\/doi.org\/10.1159\/000519817.","journal-title":"Skin Appendage Disord."},{"issue":"4","key":"1328_CR123","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.7314\/apjcp.2012.13.4.1383","volume":"13","author":"IR Kim","year":"2012","unstructured":"Kim IR, Cho J, Choi EK, et al. Perception, attitudes, preparedness and experience of chemotherapy-induced alopecia among breast cancer patients: a qualitative study. Asian Pac J Cancer Prev. 2012;13(4):1383\u20138. https:\/\/doi.org\/10.7314\/apjcp.2012.13.4.1383.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"1328_CR124","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10549-020-06063-w","volume":"186","author":"A Coolbrandt","year":"2021","unstructured":"Coolbrandt A, T\u2019Jonck A, Blauwens K, et al. Scalp cooling in breast cancer patients treated with docetaxel-cyclophosphamide: patient- and nurse-reported results. Breast Cancer Res Treat. 2021;186(3):715\u201322. https:\/\/doi.org\/10.1007\/s10549-020-06063-w.","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"1328_CR125","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.26355\/eurrev_202108_26520","volume":"25","author":"XF Shen","year":"2021","unstructured":"Shen XF, Ru LX, Yao XB. Efficacy of scalp cooling for prevention of chemotherapy induced alopecia: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(16):5090\u2013103. https:\/\/doi.org\/10.26355\/eurrev_202108_26520.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"1328_CR126","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","volume":"34","author":"RS Copeland-Halperin","year":"2019","unstructured":"Copeland-Halperin RS, Liu JE, Yu AF. Cardiotoxicity of HER2-targeted therapies. Curr Opin Cardiol. 2019;34(4):451\u20138. https:\/\/doi.org\/10.1097\/HCO.0000000000000637.","journal-title":"Curr Opin Cardiol"},{"issue":"41","key":"1328_CR127","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"Suppl 7","key":"1328_CR128","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155\u201366. https:\/\/doi.org\/10.1093\/annonc\/mds293.","journal-title":"Ann Oncol"},{"issue":"36","key":"1328_CR129","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211.","journal-title":"Eur Heart J"},{"issue":"2","key":"1328_CR130","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3949\/ccjm.88a.19150","volume":"88","author":"P Collier","year":"2021","unstructured":"Collier P, Hussain M, Popovic ZB, Griffin BP. Clevel Clin J Med. 2021;88(2):110\u20136. https:\/\/doi.org\/10.3949\/ccjm.88a.19150.","journal-title":"Clevel Clin J Med"},{"issue":"Suppl 2","key":"1328_CR131","doi-asserted-by":"publisher","first-page":"S226","DOI":"10.1016\/j.acra.2021.05.014","volume":"29","author":"S Soffer","year":"2022","unstructured":"Soffer S, Morgenthau AS, Shimon O, et al. Artificial intelligence for interstitial lung disease analysis on chest computed tomography: a systematic review. Acad Radiol. 2022;29(Suppl 2):S226\u201335. https:\/\/doi.org\/10.1016\/j.acra.2021.05.014.","journal-title":"Acad Radiol"},{"issue":"12","key":"1328_CR132","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1111\/cas.14686","volume":"111","author":"K Kumagai","year":"2020","unstructured":"Kumagai K, Aida T, Tsuchiya Y, Kishino Y, Kai K, Mori K. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020;111(12):4636\u201345. https:\/\/doi.org\/10.1111\/cas.14686.","journal-title":"Cancer Sci"},{"issue":"4","key":"1328_CR133","doi-asserted-by":"publisher","first-page":"1702519","DOI":"10.1183\/13993003.02519-2017","volume":"51","author":"IA Wiertz","year":"2018","unstructured":"Wiertz IA, van Moorsel CHM, Vorselaars ADM, Quanjel MJR, Grutters JC. Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features (IPAF). Eur Respir J. 2018;51(4):1702519. https:\/\/doi.org\/10.1183\/13993003.02519-2017.","journal-title":"Eur Respir J"},{"issue":"1","key":"1328_CR134","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001731","volume":"9","author":"A Balaji","year":"2021","unstructured":"Balaji A, Hsu M, Lin CT, et al. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. J Immunother Cancer. 2021;9(1): e001731. https:\/\/doi.org\/10.1136\/jitc-2020-001731.","journal-title":"J Immunother Cancer"},{"issue":"15","key":"1328_CR135","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-09-0344","volume":"15","author":"PH O'Donnell","year":"2009","unstructured":"O\u2019Donnell PH, Dolan ME. Cancer pharmacoethnicity: Ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009;15(15):4806\u201314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0344.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1328_CR136","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cpt.2096","volume":"109","author":"O Yin","year":"2021","unstructured":"Yin O, Xiong Y, Endo S, et al. Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors. Clin Pharmacol Ther. 2021;109(5):1314\u201325. https:\/\/doi.org\/10.1002\/cpt.2096.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1328_CR137","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/cpt.2291","volume":"110","author":"O Yin","year":"2021","unstructured":"Yin O, Iwata H, Lin CC, et al. Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan. Clin Pharmacol Ther. 2021;110(4):986\u201396. https:\/\/doi.org\/10.1002\/cpt.2291.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01328-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01328-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01328-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:16:32Z","timestamp":1697688992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01328-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":137,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1328"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01328-x","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]},"assertion":[{"value":"16 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AstraZeneca and Daiichi Sankyo provided funding to assist with the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Joanne Wing Yan Chiu received honorarium from AstraZeneca for consulting services and lectures related to the drug of interest; Soo Chin Lee received grants from Pfizer, Eisai, Taiho, ACT Genomics, Bayer, Karyopharm; consulting fees or honorarium from Pfizer, Novartis, AstraZeneca, ACT Genomics, Eli Lilly, MSD, Roche, Eisai; payments for lectures from Pfizer, Novartis, Astra Zeneca, ACT Genomics, MSD, Roche and Eisai; James Chung-man Ho received consulting fees or honorarium and lectures from AstraZeneca; Yeon Hee Park received grants AstraZeneca, Pfizer; consulting fees or honorarium from AstraZeneca, Pfizer, Lilly, MSD, Eisai, Roche, Daiichi Sankyo, MENARINI, Bixink, Everest and Novartis Pharmaceuticals; Payment for writing or review or reviewing manuscript for Lancet Oncology; and payment for lectures from AstraZeneca, Pfizer, Lilly, MSD, Eisai, Roche and Novartis Pharmaceuticals; Ta-Chung Chao has no conflicts of interest to disclose; Sung-Bae Kim received grants to their institution from Novartis, Sanofi-Aventis and DongKook Pharm Co; consulting fees or honorarium from Novartis, AstraZeneca, Lilly, Dae Hwa Pharmaceutical Co Ltd, ISU Abxis, OBI Pharma, Beigene and Daiichi Sankyo; and holds stock\/stock options from Genopeaks and NeogeneTC; Elgene Lim received consulting fees or honorarium for advisory boards from AstraZeneca; provision of writing assistance (manuscript) by Medical Pharma Services; and payment for lectures by AstraZeneca; Ching-Hung Lin has no conflicts of interest to disclose; Sherene Loi receives research funding to her institution from Novartis, Bristol Myers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, AstraZeneca and Seattle Genetics. She has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol Myers Squibb, Merck, AstraZeneca, Eli Lilly, Pfizer, Gilead Therapeutics and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, AstraZeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Pfizer, Gilead Therapeutics, Seattle Genetics, Daiichi Sankyo, Merck, Amunix, Tallac Therapeutics, Eli Lilly and Bristol Myers Squibb; Sherene Loi is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York; Su Ying Low received grants received from Boehringer Ingelheim; consulting fees or honorarium from Roche and Boehringer Ingelheim; payment for writing or reviewing manuscript from AstraZeneca; Lynette Teo consulting fees or honorarium and provision of writing assistance from AstraZeneca; Winnie Yeo consulting fees or honorarium from AstraZeneca and Daiichi Sankyo; payment for lectures from AstraZeneca and Daiichi Sankyo; Rebecca Dent has no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualisation and supervision: JWYC, RD; Writing\u2014original draft preparation: all authors; Writing\u2014review and editing: all authors. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}